Hinge Health, Inc.
In the published model solve dated 2026-Q2, anchored at $80.73, Hinge Health, Inc. (HNGE) is priced for today's economics sustained for ~6.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Hinge Health sells digital musculoskeletal care to employers and health plans on an annual subscription where, per its 10-K, ⟦clients only pay for members that engage with our programs⟧, so engagement is both the product and the revenue lever. • The defining recent fact is the profitability inflection: Q1 2026 revenue grew 47% to $182 million with an 85% gross margin and a 25% operating margin, and free cash flow turned to $42 million, a tenfold jump year over year. [Source: Q1 2026 earnings c
Is HNGE overvalued? See what's priced in →
194 institutional managers reported holding HNGE in 13F filings for the quarter ended 2026-03-31. Together they hold about 67% of the company; the top 10 hold 35%. 56 opened new positions that quarter. Held by Vanguard Group, Arrowstreet Capital, Citadel Advisors, among others. On the short side, 5.8M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (2.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
No open-market insider buys on file at HNGE over the trailing three years. Absence is a fact about the company, not a signal. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HNGE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2025-11-08 | -9.4% | +7.6% |
| 2026-03-04 | +20.5% | +20.0% |
| 2026-05-08 | +12.0% | pending |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HNGE's latest 8-K filings: 2026-08-04 (items 2.02, 7.01, 8.01, 9.01); 2026-06-09 (items 7.01, 9.01); 2026-06-04 (items 5.07); 2026-05-05 (items 2.02, 7.01, 9.01); 2026-03-17 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.